ARISTO
Aristo Bio-Tech & Lifescience financials
- Market cap
- ₹74 Cr
- Sector
- Chemicals
What Aristo Bio-Tech & Lifescience Ltd does
Aristo Bio-Tech and Lifescience manufactures, formulates, packages and job-works a range of agrochemicals — insecticides, herbicides, fungicides, plant growth regulators and other pesticides — at its works in Manjusar, Taluka Savli, Vadodara, Gujarat. The company holds 257 products registered with the Central Insecticides Board & Registration Committee (CIB&RC) for manufacture and sale. Products are sold directly to customers and also produced on a job-work basis, supplied across 20 Indian states and exported to 15 countries.
Segments
- Agrochemicals (Crop Protection)
- Products registered with CIB&RC
- 257
- Domestic states served
- 20 states
- Export countries
- 15 countries
- Manufacturing facility
- 1 (Manjusar, Vadodara, Gujarat)
- Permanent employees
- 66 (as on Mar 31, 2025)
- In-house quality control lab testing methods
- HPLC, UV Spectrograph, GC
Quarterly results
Q4 FY26: revenue down 4.5%, net profit up 200.0% against the same quarter last year.
| Line item | Q2 FY23 | Q4 FY23 | Q2 FY24 | Q4 FY24 | Q2 FY25 | Q4 FY25 | Q2 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 129 | 89 | 133 | 112 | 214 +66% | 104 +17% | 256 +92% | 107 −4% |
| EBITDA | 5 | 4 | 5 | 3 | 8 +60% | 1 −75% | 8 +60% | 8 +167% |
| Net profit | 3 | 1 | 3 | 1 | 5 +67% | 0 −100% | 4 +33% | 3 +200% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −16.9% 1Y
1Y: ₹130 on 10 Sept 2025 → ₹108. High ₹140 (15 Sept 2025), low ₹75 (30 Mar 2026).
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹5 Cr | ₹5 Cr | ₹7 Cr | ₹7 Cr | ₹7 Cr | ₹7 Cr |
| Reserves | ₹8 Cr | ₹10 Cr | ₹23 Cr | ₹27 Cr | ₹35 Cr | ₹38 Cr |
| Borrowings | ₹22 Cr | ₹25 Cr | ₹22 Cr | ₹21 Cr | ₹35 Cr | ₹35 Cr |
| Other liabilities | ₹46 Cr | ₹37 Cr | ₹47 Cr | ₹73 Cr | ₹174 Cr | ₹75 Cr |
| Total liabilities | ₹81 Cr | ₹77 Cr | ₹100 Cr | ₹127 Cr | ₹250 Cr | ₹155 Cr |
| Fixed assets | ₹12 Cr | ₹14 Cr | ₹16 Cr | ₹22 Cr | ₹24 Cr | ₹24 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹69 Cr | ₹63 Cr | ₹83 Cr | ₹106 Cr | ₹226 Cr | ₹131 Cr |
| Total assets | ₹81 Cr | ₹77 Cr | ₹100 Cr | ₹127 Cr | ₹250 Cr | ₹155 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Mar 2026
The ownership split has held steady since Mar 2025. The shareholder count shrank 12% to 453.
- Promoters
- 73.4%
- Public
- 26.6%
Since Mar 2025
- Promoters 0.00 pp
- Public 0.00 pp
How it drifted, 7 quarters
Ownership split by quarter, oldest first. Mar '23: Promoters 73.4%, Public 26.6%.Sep '23: Promoters 73.4%, Public 26.6%.Mar '24: Promoters 73.4%, Public 26.6%.Sep '24: Promoters 73.4%, Public 26.6%.Mar '25: Promoters 73.4%, Public 26.6%.Sep '25: Promoters 73.4%, Public 26.6%.Mar '26: Promoters 73.4%, Public 26.6%.
Who is on the register
Named in the Mar 2026 filing
Every holder of Aristo Bio-Tech & Lifescience Ltd above SEBI's 1% disclosure line, and what changed since Sep 2025.
| Holder | Stake | Change |
|---|---|---|
| Narendra Singh Barhat | 33.54% | unchanged |
| Ketankumar Harkantbhai Joshi | 10.58% | unchanged |
| Kusum Barhat | 9.18% | unchanged |
| Himanshu Barhat | 7.56% | unchanged |
| Neeta K Joshi | 7.05% | unchanged |
| N S Barhat Huf | 3.67% | unchanged |
| Falguni Shreyash Shah | 3.13% | unchanged |
| Kabra Sunil Murlimanohar | 2.35% | unchanged |
| Richa N Barhat | 1.84% | unchanged |
| Llp | 0.02% | unchanged |
| Harkant Joshi | 0.00% | unchanged |
| Kinlak Biotech ( Propritor - Narendra Singh Barhat) | 0.00% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Aristo Bio-Tech & Lifescience Ltd
Guides on how to read this kind of business and the numbers that matter.